From the Wires
CLAAD Responds to Draft Guidance on Abuse-Deterrent Opioids
By: PR Newswire
Jan. 9, 2013 06:34 PM
WASHINGTON, Jan. 9, 2013 /PRNewswire-USNewswire/ -- Michael Barnes, Executive Director of the Center for Lawful Access and Abuse Deterrence (CLAAD) today released the following statements in response to the Obama-Biden Administration's issuance of draft guidance on the evaluation and labeling of abuse-deterrent opioid medications:
About the Center for Lawful Access and Abuse Deterrence
The non-profit Center for Lawful Access and Abuse Deterrence (CLAAD) coordinates a comprehensive national effort to prevent the diversion, misuse, and abuse of prescription medications while ensuring adequate medical care for patients in need. CLAAD enables health professionals, law enforcement, businesses, and government, among many other entities, to share resources and work together to reduce prescription drug abuse, addiction, and overdoses. CLAAD's National Prescription Drug Abuse Prevention Strategy has been endorsed by 30 non-profit organizations and may be accessed online at www.claad.org. Follow @claad_coalition.
Latest Cloud Developer Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week